ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Their core work

AP-HP is the largest university hospital system in Europe, encompassing 39 hospitals across the Paris region. In H2020, they serve as a major clinical partner bringing patient cohorts, clinical trial infrastructure, and biomarker validation capabilities to multinational health research consortia. Their contribution centers on running clinical trials, providing real-world patient data for drug and therapy validation, and translating laboratory findings into hospital-grade diagnostics and treatments — particularly in liver disease, rare diseases, gene therapy, and vaccine development.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), AP-HP focused heavily on regenerative medicine, stem cell therapies, liver cirrhosis treatments, and traditional clinical trial participation — reflected in keywords like stem cell, cell therapy, brain repair, and liver cirrhosis. By the later period (2019–2021), their portfolio shifted toward omics-based diagnostics, rare diseases, AI/machine learning applications, pandemic preparedness (COVID-19), and vaccine/immunotherapy development. This evolution tracks the broader European health research agenda moving from individual disease therapies toward data-driven precision medicine and crisis response.

AP-HP is integrating AI and digital tools into its clinical infrastructure while expanding its rare disease and pandemic readiness capabilities — making them an increasingly valuable partner for projects combining clinical data with computational approaches.

How they like to work

AP-HP overwhelmingly participates as a consortium partner rather than a coordinator — leading only 1 of 72 projects (PEVIA). This is typical for a large hospital system whose primary value lies in patient access, clinical infrastructure, and regulatory-ready trial sites rather than project management. With 968 unique partners across 59 countries, they are a highly connected hub, working in large multinational consortia and bringing credibility and scale to any health research proposal.

AP-HP has collaborated with 968 unique partners across 59 countries, making them one of the most broadly networked clinical organizations in H2020. Their partnerships span all of Europe with strong connections to IMI public-private partnerships and pan-European rare disease and vaccine networks.

What sets them apart

AP-HP's unmatched advantage is scale: 39 hospitals, 100,000+ staff, and access to one of Europe's largest and most diverse patient populations — critical for any consortium needing large clinical cohorts or multi-site trial validation. Unlike specialized research institutes, they offer end-to-end translational capability from biomarker discovery through Phase II/III trials within a single institutional framework. For consortium builders, including AP-HP signals clinical credibility and dramatically improves patient recruitment feasibility.

Highlights from their portfolio

• PEVIA
  Their only coordinated project (EUR 1.3M) — a Pan-Ebola vaccine initiative, signaling leadership ambition in vaccine development.
• Solve-RD
  Part of the European Reference Networks for rare diseases, positioning AP-HP at the center of Europe's unsolved rare disease diagnostic effort.
• R-LiNK
  Largest single-project funding (EUR 857K) focused on personalizing lithium treatment for bipolar disorder using biomarkers and prediction models.